Growth Hormone Peptides Compared: Ipamorelin, CJC-1295, and Tesamorelin

Search for "growth hormone peptides" and you will find ipamorelin, CJC-1295, and tesamorelin grouped together as if they were interchangeable. They are not. They belong to two mechanistically distinct classes, they have very different levels of human evidence, and their regulatory status ranges from an FDA-approved prescription drug to unapproved research chemicals. Understanding those differences is the whole point of this comparison. We will cover how each works, what evidence exists, and where each sits legally, with links to the ipamorelin, CJC-1295, and tesamorelin research profiles for the deeper detail. If you want the underlying biology first, our primer on growth hormone secretagogues explained is the natural starting point.

Two mechanisms, not one

The single most useful thing to understand is that "growth hormone peptide" describes an outcome, not a mechanism. These compounds aim to increase the body's own release of growth hormone (GH) from the pituitary, rather than injecting GH directly. But they get there by two different doors.

GHRH analogs

The body naturally releases growth hormone in response to growth hormone-releasing hormone (GHRH), a signal from the hypothalamus. A GHRH analog is a peptide designed to mimic that natural signal, binding the GHRH receptor on the pituitary and prompting GH release along the normal physiological pathway. Both CJC-1295 and tesamorelin are GHRH analogs. Tesamorelin in particular is a stabilized version of human GHRH engineered to resist rapid breakdown.

Ghrelin mimetics (GH secretagogues)

There is a second, parallel pathway. Ghrelin, the hormone better known for stimulating appetite, also triggers GH release by acting on a different receptor, the growth hormone secretagogue receptor. Peptides that mimic ghrelin at this receptor are called GH secretagogues or ghrelin mimetics. Ipamorelin belongs to this class. Ipamorelin is often described as relatively selective, meaning it aims to trigger GH release with less of the appetite stimulation, cortisol, or prolactin effects seen with some older secretagogues.

The reason this two-door structure matters is that the pathways are complementary. GHRH analogs and ghrelin mimetics act on different receptors, which is exactly why they are sometimes studied or marketed together: the idea is that hitting both doors produces a larger GH pulse than either alone. That combination logic is the origin of the common "CJC-1295 plus ipamorelin" pairing.

Why "natural" GH release is not automatically safer

A recurring marketing theme is that because these peptides stimulate the body's own GH release rather than injecting synthetic GH, they must be gentler or more physiological. This deserves a skeptical look. It is true that secretagogues and GHRH analogs preserve some of the body's pulsatile release pattern and its feedback loops, which in principle is different from flooding the system with exogenous GH. But "works through a natural pathway" is not the same as "proven safe." Chronically elevating GH and IGF-1 by any route raises the same open questions about long-term effects, and the feedback systems that these compounds engage can themselves adapt over time. The physiological-pathway argument is a mechanistic talking point, not a substitute for the long-term human safety data that these compounds, with the partial exception of tesamorelin, simply do not have.

The compounds side by side

Ipamorelin: the selective ghrelin mimetic

Ipamorelin is a short synthetic peptide that acts as a ghrelin mimetic. In pharmacology studies it reliably stimulates GH release, and its selling point is selectivity: compared with earlier secretagogues, it was designed to raise GH with a cleaner side-effect profile, particularly less impact on appetite, cortisol, and prolactin.

The critical caveat is the evidence gap. Ipamorelin has been characterized in preclinical and early pharmacology work, but it does not have a body of large, long-term human outcome trials demonstrating benefits for body composition, aging, or performance. It is not an approved drug for human use. It is best understood as a research compound: mechanistically interesting, but with human outcome evidence that remains limited. A fair rating for real-world benefit claims is Insufficient evidence.

CJC-1295: the long-acting GHRH analog

CJC-1295 is a GHRH analog engineered for a longer duration of action than native GHRH. It exists in forms with and without a technology (DAC, drug affinity complex) that extends its half-life considerably by binding to albumin in the blood, which is why you will see references to "CJC-1295 with DAC" and "without DAC."

Like ipamorelin, CJC-1295 has been studied enough to characterize its effect on GH and IGF-1 levels in early human pharmacology work, but it lacks the large, long-term outcome trials that would establish safety and benefit for the purposes it is marketed for. It, too, is not approved for human use, and its human outcome evidence is limited. The same Insufficient evidence caveat applies to benefit claims.

Tesamorelin: the approved outlier

Tesamorelin is the one member of this group that stands apart, and the difference is regulatory as much as pharmacological. Tesamorelin is a stabilized GHRH analog that is FDA-approved, under the brand name Egrifta, for a specific medical indication: the reduction of excess visceral abdominal fat in people with HIV-associated lipodystrophy.

This matters enormously. Tesamorelin went through the full clinical trial process for its approved indication, with randomized controlled trials showing reductions in visceral adipose tissue in that patient population. That gives it a genuine evidence base, at least Moderate evidence for its approved use, that the other two simply do not have. But two boundaries need stating clearly. First, that evidence is specific to its approved population and endpoint, not a general anti-aging or physique claim. Second, tesamorelin is a prescription medicine that requires medical supervision, and its approval does not license the broad off-label uses often attached to it online.

The evidence gap is the headline

Step back and the comparison resolves into a clear hierarchy of evidence, which is the single most important takeaway:

• Tesamorelin has real, approval-grade human trial evidence, but only for a specific medical condition, and it is a supervised prescription drug.
• CJC-1295 and ipamorelin have early pharmacological characterization but lack large, long-term human outcome trials. They are unapproved research compounds.

This gap is easy to miss because all three are discussed in the same breath and all three raise GH by some route. But "raises growth hormone in a pharmacology study" and "produces proven, safe benefits over time in humans" are very different claims. The former is documented for all three; the latter is only established, and only within a narrow indication, for tesamorelin. Confusing the two is the central error in most growth-hormone-peptide marketing.

Regulatory and anti-doping status

The regulatory picture reinforces the same divide and deserves to be spelled out plainly.

Tesamorelin is an approved prescription drug for its specific indication and must be used under medical supervision. Ipamorelin and CJC-1295 are not approved for human use; they are typically sold as "research chemicals," a designation that carries no assurance of purity, dosing accuracy, or safety, and that sits outside the protections of the approved-drug framework.

For anyone subject to anti-doping rules, all of these compounds are relevant in a different way. GH-releasing peptides, GH secretagogues, and GHRH analogs fall under the categories prohibited by the World Anti-Doping Agency (WADA), both in and out of competition. Athletes tested under WADA-compliant programs should understand that this entire class is prohibited, and that includes ipamorelin, CJC-1295, and tesamorelin. That is a factual status point, not a performance endorsement.

How to compare them honestly

If you are trying to make sense of these three compounds, a few principles keep the comparison grounded:

• Sort by mechanism first. Tesamorelin and CJC-1295 are GHRH analogs; ipamorelin is a ghrelin mimetic. This explains why they are sometimes paired and why they are not redundant.
• Sort by evidence second. Tesamorelin has approval-grade trials for one indication. The other two have early pharmacology but no large outcome trials.
• Sort by regulatory status third. One is an approved, supervised prescription drug. Two are unapproved research chemicals with no quality guarantees.
• Keep indications narrow. Even tesamorelin's strong evidence applies only to its approved population and endpoint, not to general aging or physique goals.
• Remember the anti-doping status. The whole class is WADA-prohibited for tested athletes.

Run the three through those filters and the "growth hormone peptide" umbrella dissolves into a much more accurate picture: one legitimate, narrowly indicated prescription medicine, and two research compounds whose human benefit claims outrun their evidence. That is a less exciting story than the marketing tells, but it is the honest one. For the mechanistic foundation behind all of this, revisit our detailed explainer on growth hormone secretagogues, and for the broader longevity context in which GH signaling is often discussed, see our overview of NAD and aging.